Additional patent for AI-monitoring of medical devices will be granted in the US
The U.S. Patent and Trademark Office has announced that they will grant Brighter an additional patent for data-driven monitoring of mobile medical devices.
The patent secures the rights to a system that enables AI-driven monitoring of the functionality in medical devices in interaction with relevant data from mobile phones.
“We have seen great potential in the US market for quite some time, and this patent strengthens our position for the unique opportunities that are emerging with digital care providers need to secure relevant data not only from apps but also from medical devices, says Henrik Norström,” CEO of Brighter.
A data-driven monitoring makes it possible for continuous remote validation of data collection through advanced AI technology, which is required for digital care providers to be able to provide care where an app is not enough.
For further information, please contact:
Henrik Norström, CEO
+46 733 40 30 45
Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, email@example.com, www.eminova.se.
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award.
The Company's shares are listed on Nasdaq First North Growth Market/BRIG.